Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) harboring BIM deletion polymorphism (BIM deletion) have poor responses to EGFR TKI. Mechanistically, the BIM deletion induces preferential splicing of the non‐functional exon 3‐containing isoform over th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Takeuchi, Shinji, Hase, Tetsunari, Shimizu, Shinobu, Ando, Masahiko, Hata, Akito, Murakami, Haruyasu, Kawakami, Takahiro, Nagase, Katsuhiko, Yoshimura, Kenichi, Fujiwara, Tadami, Tanimoto, Azusa, Nishiyama, Akihiro, Arai, Sachiko, Fukuda, Koji, Katakami, Nobuyuki, Takahashi, Toshiaki, Hasegawa, Yoshinori, Ko, Tun Kiat, Ong, S. Tiong, Yano, Seiji
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7004511/
https://ncbi.nlm.nih.gov/pubmed/31782583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados